EZZ Stock Overview
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
EZZ Life Science Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.10 |
| 52 Week High | AU$4.97 |
| 52 Week Low | AU$0.45 |
| Beta | 0.67 |
| 1 Month Change | 24.00% |
| 3 Month Change | -23.27% |
| 1 Year Change | 376.92% |
| 3 Year Change | 507.84% |
| 5 Year Change | n/a |
| Change since IPO | 167.24% |
Recent News & Updates
Recent updates
EZZ Life Science Holdings Limited (ASX:EZZ) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Nov 04
EZZ Life Science Holdings Limited's (ASX:EZZ) Shares Leap 41% Yet They're Still Not Telling The Full Story
Aug 28EZZ Life Science Holdings Limited (ASX:EZZ) Stock Catapults 29% Though Its Price And Business Still Lag The Market
Jun 05There's No Escaping EZZ Life Science Holdings Limited's (ASX:EZZ) Muted Earnings Despite A 28% Share Price Rise
Apr 02Here's Why We Think EZZ Life Science Holdings (ASX:EZZ) Is Well Worth Watching
Feb 09EZZ Life Science Holdings Limited's (ASX:EZZ) Share Price Is Matching Sentiment Around Its Earnings
Oct 18EZZ Life Science Holdings' (ASX:EZZ) Promising Earnings May Rest On Soft Foundations
Mar 06Calculating The Fair Value Of EZZ Life Science Holdings Limited (ASX:EZZ)
Nov 22Shareholder Returns
| EZZ | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | 6.5% | 4.3% | 0.7% |
| 1Y | 376.9% | 17.4% | 6.8% |
Return vs Industry: EZZ exceeded the Australian Life Sciences industry which returned 17.4% over the past year.
Return vs Market: EZZ exceeded the Australian Market which returned 6.8% over the past year.
Price Volatility
| EZZ volatility | |
|---|---|
| EZZ Average Weekly Movement | 12.2% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: EZZ's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: EZZ's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Qizhou Qin | ezzlife.com.au |
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally. The company operates through Brought in Lines and Company Owned Products segments. It is also involved in the wholesale distribution of the EAORON branded skin care products to retailers.
EZZ Life Science Holdings Limited Fundamentals Summary
| EZZ fundamental statistics | |
|---|---|
| Market cap | AU$146.32m |
| Earnings (TTM) | AU$6.96m |
| Revenue (TTM) | AU$66.44m |
20.5x
P/E Ratio2.2x
P/S RatioIs EZZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EZZ income statement (TTM) | |
|---|---|
| Revenue | AU$66.44m |
| Cost of Revenue | AU$15.50m |
| Gross Profit | AU$50.95m |
| Other Expenses | AU$43.98m |
| Earnings | AU$6.96m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 76.68% |
| Net Profit Margin | 10.48% |
| Debt/Equity Ratio | 0% |
How did EZZ perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield16%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 08:08 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EZZ Life Science Holdings Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Lodge Partners Pty Ltd. |
| Chris Kallos | MST Financial Services Pty Limited |